News

The study presented at the 2021 AAN Meeting follows the complete response letter issued by the FDA to Acadia Pharmaceuticals due to deficiencies in their sNDA.

Agency requests additional analyses on the novel mechanism of action on the serum phosphorus treatment for chronic kidney disease patients on dialysis.

Marla Dubinsky, MD, discusses what needs to be done to improve care for children with ulcerative colitis.

New data show blood pressure lowering medication can be effective in reducing cardiovascular events in adults, regardless of blood pressure levels or history of cardiovascular risk.

New data show that youths with type 1 diabetes perceive their sleep as disrupted, but investigators find similar objective outcomes in youths without diabetes.

The CDC recently recorded the largest estimate of overdose deaths in a 12-month period in US History.

The innovative technology is associated with significantly improved time to tear breakup, meibum quality, and improved inflammatory markers.

Not all individuals with sarcoidosis need to be treated.

Researchers recently completed a 16-week phase 2b trial for patients with ulcerative colitis.

Marla Dubinsky, MD, discusses what adding adalimumab to the pediatric ulcerative colitis toolbox means for treatment strategies.

Men, individuals with 15 years of type 2 diabetes, and those older than 55 years old had the greatest absolute risk reduction.

New data affirms a low rate of hepatitis B vaccination responsiveness among patients with hepatitis B core antibodies.

The study authors said that decentralizing dispensation of hepatitis C treatment re-engages patients.

David I. Bernstein, MD of the University of Cincinnati College of Medicine discusses the recent approval of short ragweed pollen allergen extract tablet (RAGWITEK) for the treatment of children and adolescents.

New data find significant associations between every five-year earlier onset of diabetes and a higher hazard rate of dementia, in patients aged 35-75 years old.

There is a need for cost-effective treatments for HCV in low-income countries.

Charles Argoff, MD, leads a discussion on the use of pain contracts versus pain agreements between clinicians and patients to bring about desired outcomes.

Experts discuss the need for and impact of peer-to-peer discussion initiatives, as well as the impact telemedicine utilization has had on the opioid crisis.

The US will send unused vaccines to India to help combat the growing pandemic.

The amount of minimally invasive surgeries has increased between 2010-2017.

A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

An intervention can aid children experiencing severe health effects when exposed to opioid use by parents.

Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.

New data has investigators caution against the discontinuation of ulcerative colitis treatment, due to threat of relapse.

A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.